trial

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

NCTId NCT04296604

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

— · Recruiting

Enrollment 600 (estimated)

Sponsored by Massachusetts General Hospital

Primary completion 2026-04

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Recruiting

Enrollment

600 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

Single

Start

2014-09

Primary completion

2026-04

Eligibility

ALL · 18 Years · 65 Years

Interventions & indications

Drugs

transcranial direct current stimulation

Indications

Bipolar Disorder Major Depressive Disorder Attention Deficit Disorder with Hyperactivity Borderline Personality Disorder Brain Injuries, Traumatic Depressive Disorder, Major Borderline Personality Disorder Bipolar Disorder Schizophrenia Schizophrenia Substance-Related Disorders Attention Deficit Hyperactivity Disorder

Investigators

Joan Camprodon, MD, PhD, MPHPrincipal Investigator

Sites

1 total

Boston, United States

Facts & assertions

4 sourced

Enrollment

600

Phase

Primary Completion Date

2026-04

Status

RECRUITING

relationships

The graph out of here

drug

transcranial direct current stimulation

drug

lead_sponsor

Massachusetts General Hospital

company

indication

Bipolar Disorder

indication

Major Depressive Disorder

indication

Attention Deficit Disorder with Hyperactivity

indication

investigator

Joan Camprodon, MD, PhD, MPH

person